Pellkofer, Hannah Luise

[["dc.bibliographiccitation.firstpage","1213"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","1216"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Freytag, Saskia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Strupp, Michael"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1097/MAO.0000000000001510"],["dc.identifier.issn","1531-7129"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75432"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","38"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Current Neurology and Neuroscience Reports"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Kretzschmar, Benedikt"],["dc.contributor.author","Pellkofer, Hannah L."],["dc.contributor.author","Weber, Martin S."],["dc.date.accessioned","2018-11-07T10:16:31Z"],["dc.date.available","2018-11-07T10:16:31Z"],["dc.date.issued","2016"],["dc.description.abstract","Three oral disease-modifying drugs-fingolimod, teriflunomide, and dimethyl fumarate (DMF)-are available for treatment of relapsing forms of multiple sclerosis (MS). All three agents were approved in the last decade, primarily on the basis of a moderate to substantial reduction in the occurrence of MS relapses and central nervous system lesion formation detected by MRI. In the trials leading to approval, the first oral disease-modifying drug, fingolimod, reduced the annualized relapse rate (ARR) from 0.40 in placebo-treated patients to 0.18 (FREEDOMS) and from 0.33 in patients treated with interferon beta(1a) intramuscularly to 0.16 (TRANSFORMS). Teriflunomide, approved on the basis of the two placebo-controlled trials TEMSO and TOWER, demonstrated a reduction in the ARR from 0.54 to 0.37 and from 0.50 to 0.32 respectively. The latest oral MS medication, approved in 2014, is DMF, which had been used in a different formulation for treatment of psoriasis for decades. In the 2-year DEFINE study, the proportion of patients with a relapse was reduced to 27 %, compared with 46 % in placebo arm, whereas in the CONFIRM trial, the ARR was reduced from 0.40 (placebo) to 0.22 in the DMF-treated group of patients. In this review, we will elucidate the mechanisms of action of these three medications and compare their efficacy, safety, and tolerability as a practical guideline for their use. We will further discuss effects other than relapse reduction these small molecules may exert, including potential activities within the central nervous system, and briefly summarize emerging data on new oral MS drugs in clinical development."],["dc.identifier.doi","10.1007/s11910-016-0639-4"],["dc.identifier.isi","000372534500001"],["dc.identifier.pmid","26944956"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41053"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1534-6293"],["dc.relation.issn","1528-4042"],["dc.title","The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","995"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Headache The Journal of Head and Face Pain"],["dc.bibliographiccitation.lastpage","1003"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Schankin, Christoph J."],["dc.contributor.author","Kaestele, Fabian"],["dc.contributor.author","Gerdes, Lisa Ann"],["dc.contributor.author","Winkler, Tobias"],["dc.contributor.author","Csanadi, Endy"],["dc.contributor.author","Hoegen, Tobias"],["dc.contributor.author","Pellkofer, Hannah L."],["dc.contributor.author","Paulus, Walter J."],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Straube, Andreas"],["dc.date.accessioned","2018-11-07T10:13:15Z"],["dc.date.available","2018-11-07T10:13:15Z"],["dc.date.issued","2016"],["dc.description.abstract","ObjectiveWe tested the hypotheses (i) that autoimmune encephalitis is associated with new-onset headache, and (ii) that the occurrence of headache is associated with the presence of anti-N-methyl-D-aspartate (NMDA)-receptor antibodies. BackgroundAutoimmune encephalitis presents with cognitive dysfunction as well as neuro-psychiatric symptoms. Its pathophysiology might involve antibody-mediated dysfunction of the glutamatergic system as indicated by the presence of anti-NMDA-receptor antibodies in some patients. MethodsIn this cross-sectional study, patients with autoimmune encephalitis were assessed with a standardized interview for previous headache and headache associated with autoimmune encephalitis. Headache was classified according to the International Classification of Headache Disorders, second edition. Clinical and paraclinical findings were correlated with the occurrence of headache. ResultsOf 40 patients with autoimmune encephalitis, 19 did not have a history of headache. Of those, nine suffered from encephalitis-associated headache. Seven of these nine had anti-NMDA-receptor antibodies in contrast to only two among the remaining 10 patients without new-onset headache (P=.023, odds ratio: 14, 95% confidence interval: 1.5; 127). In most patients headache occurred in attacks on more than 15 days/month, was severe, and of short duration (less than 4 hours). International Headache Society criteria for migraine were met in three patients. ConclusionsNew-onset headache is a relevant symptom in patients with autoimmune encephalitis who have no history of previous headache, especially in the subgroup with anti-NMDA-receptor antibodies. This indicates a thorough investigation for secondary headaches including anti-NMDA-R antibodies for patients with new-onset headache and neuropsychiatric findings. Glutamatergic dysfunction might be important for the generation of head pain but may only occasionally be sufficient to trigger migraine-like attacks in nonmigraineurs."],["dc.description.sponsorship","German Migraine and Headache Society; Friedrich Baur Foundation [58/14]"],["dc.identifier.doi","10.1111/head.12853"],["dc.identifier.isi","000379154300008"],["dc.identifier.pmid","27241874"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40392"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1526-4610"],["dc.relation.issn","0017-8748"],["dc.title","New-Onset Headache in Patients With Autoimmune Encephalitis Is Associated With anti-NMDA-Receptor Antibodies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e407"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e418"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Ringelstein, Marius"],["dc.contributor.author","Harmel, Jens"],["dc.contributor.author","Zimmermann, Hanna"],["dc.contributor.author","Brandt, Alexander U."],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Haarmann, Axel"],["dc.contributor.author","Buttmann, Mathias"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.author","Schroeder, Christoph"],["dc.contributor.author","Ayzenberg, Ilya"],["dc.contributor.author","Kleiter, Ingo"],["dc.contributor.author","Hellwig, Kerstin"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Wildemann, Brigitte"],["dc.contributor.author","Rommer, Paulus"],["dc.contributor.author","Weber, Martin S."],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Röpke, Luise"],["dc.contributor.author","Geis, Christian"],["dc.contributor.author","Retzlaff, Nele"],["dc.contributor.author","Zettl, Uwe"],["dc.contributor.author","Deppe, Michael"],["dc.contributor.author","Klotz, Luisa"],["dc.contributor.author","Young, Kim"],["dc.contributor.author","Stellmann, Jan-Patrick"],["dc.contributor.author","Kaste, Matthias"],["dc.contributor.author","Kermer, Pawel"],["dc.contributor.author","Marouf, Wael"],["dc.contributor.author","Lauda, Florian"],["dc.contributor.author","Tumani, Hayrettin"],["dc.contributor.author","Graf, Jonas"],["dc.contributor.author","Klistorner, Alexander"],["dc.contributor.author","Hartung, Hans-Peter"],["dc.contributor.author","Aktas, Orhan"],["dc.contributor.author","Albrecht, Philipp"],["dc.date.accessioned","2020-12-10T18:41:46Z"],["dc.date.available","2020-12-10T18:41:46Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1212/WNL.0000000000008684"],["dc.identifier.eissn","1526-632X"],["dc.identifier.issn","0028-3878"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77670"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e1184"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","e1196"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Hümmert, Martin W."],["dc.contributor.author","Schöppe, Louisa M."],["dc.contributor.author","Bellmann-Strobl, Judith"],["dc.contributor.author","Siebert, Nadja"],["dc.contributor.author","Paul, Friedemann"],["dc.contributor.author","Duchow, Ankelien"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Kümpfel, Tania"],["dc.contributor.author","Havla, Joachim"],["dc.contributor.author","Jarius, Sven"],["dc.contributor.author","Trebst, Corinna"],["dc.contributor.authorgroup","on behalf of the Neuromyelitis Optica Study Group (NEMOS)"],["dc.date.accessioned","2022-04-01T10:02:06Z"],["dc.date.available","2022-04-01T10:02:06Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19–83] years, median disease duration 7 [0–43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0–8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225–68,293 or US dollars [USD] 70,297, 95% CI 60,445–80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65–0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%), especially immunotherapeutics. Costs showed a positive correlation with disease severity (ρ = 0.56, 95% CI 0.45–0.65); in the EDSS score 6.5 to 8.5 subgroup, the mean annual costs were €129,687 (95% CI 101,946–160,336 or USD 153,031, 95% CI 120,296–189,196). The HRQoL revealed a negative correlation to disease severity (ρ = −0.69, 95% CI −0.76 to −0.61); in the EDSS score 6.5 to 8.5 subgroup, the EQ-5D-5L mean index value was 0.195 (95% CI 0.13–0.28). Neither antibody status nor disease duration influenced the total annual costs or HRQoL. Discussion These German data from the era without approved preventive immunotherapies show enormous effects of the diseases on costs and quality of life. An early and cost-effective therapy should be provided to prevent long-term disability and to preserve quality of life."],["dc.identifier.doi","10.1212/WNL.0000000000200052"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105822"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease"],["dc.title.alternative","CHANCE\n NMO\n Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","225"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Brain Pathology"],["dc.bibliographiccitation.lastpage","233"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Barrantes-Freer, Alonso"],["dc.contributor.author","Engel, Aylin Sophie"],["dc.contributor.author","Rodríguez-Villagra, Odir Antonio"],["dc.contributor.author","Winkler, Anne"],["dc.contributor.author","Bergmann, Markus"],["dc.contributor.author","Mawrin, Christian"],["dc.contributor.author","Kuempfel, Tania"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Metz, Imke"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Hernández-Durán, Silvia"],["dc.contributor.author","Schippling, Sven"],["dc.contributor.author","Rushing, Elisabeth J."],["dc.contributor.author","Frank, Stephan"],["dc.contributor.author","Glatzel, Markus"],["dc.contributor.author","Matschke, Jakob"],["dc.contributor.author","Hartmann, Christian"],["dc.contributor.author","Reifenberger, Guido"],["dc.contributor.author","Müller, Wolf"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.contributor.author","Brück, Wolfgang"],["dc.contributor.author","Stadelmann, Christine"],["dc.date.accessioned","2020-12-10T18:27:05Z"],["dc.date.available","2020-12-10T18:27:05Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/bpa.12496"],["dc.identifier.issn","1015-6305"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76237"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination"],["dc.title.alternative","Diagnostic red flags"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]